Latest ketoconazole Stories
Connie K. Ho for redOrbit.com – Your Universe Online There’s the saying, “An apple a day, keeps the doctor away.” For cancer patients, it might be lucrative to drink grapefruit juice instead. According to a new clinical trial, drinking a glass of grapefruit juice a day allows patients to have the same benefits as the effect produced from three times of an anti-cancer drug. The researchers believe that the grapefruit juice could help patients take smaller amounts of the...
Research on the fungus that ranks as one cause of dandruff — the embarrassing nuisance that, by some accounts, afflicts half of humanity — is pointing scientists toward a much-needed new treatment for the condition's flaking and itching. The advance is the topic of a report in ACS' Journal of Medicinal Chemistry. Claudiu T. Supuran and colleagues explain that dandruff involves an excessive shedding of dead skin cells from the scalp. In people without dandruff, it takes about 30 days...
ALLEGAN, Mich., Aug. 30, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina® Ketoconazole Foam, 2%. Perrigo has commenced shipping of the product and was first to file, enabling 180 days of marketing exclusivity. This product is part of the Perrigo/Cobrek collaboration. Extina®...
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." The Symposium is currently taking place in Geneva, Switzerland. The Phase II clinical trial of CB7630 (COU-AA-002) is being conducted at the University of California, San Francisco Comprehensive Cancer Center with...
MethylGene, a clinical stage biopharmaceutical company, has announced that Health Canada has approved the company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene expects to initiate a Phase I clinical trial in Canada in October 2008. The goal of this trial will be to assess the safety, pharmacokinetics and tolerability of the compound in healthy volunteers. MGCD290...
Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePak(TM) for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term. The two products in Xolegel CorePak are new Xebcort(TM) Gel, a 1% hydrocortisone gel, and Xolegel(R) (ketoconazole, USP) Gel, 2%. Xebcort Gel provides quick symptom relief and is presented as a 0.8...
Quinnova Pharmaceuticals, Inc. announced today the commercial launch of its second, water-lipid based foam prescription drug product utilizing the patented Proderm TechnologyTM. TERSI FOAM™, containing 2.25 percent selenium sulfide as its active ingredient, provides physicians and patients with the first foam, leave-on selenium sulfide therapy for the treatment of seborrheic dermatitis and tinea versicolor of the skin. "TERSI FOAM's cosmetically elegant, leave-on therapy and the...
